Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

[Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].

Watanabe T, Nishiwaki N, Kajiwara Y, Okamoto T, Miyamoto M, Kohjima T, Watanabe Y, Yoshino K, Kawai T, Toda K, Nobuhisa T, Endo Y, Matsumoto Y, Watanabe N, Kai K, Sato S.

Gan To Kagaku Ryoho. 2013 Jan;40(1):71-4. Japanese.

PMID:
23306921
[PubMed - indexed for MEDLINE]
2.

A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.

Zhi J, Chen E, Major P, Burns I, Robinson B, McKendrick J, Rittweger K, Abt M, Goldstein D.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1199-206. doi: 10.1007/s00280-011-1606-z. Epub 2011 Mar 16.

PMID:
21409383
[PubMed - indexed for MEDLINE]
3.

[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].

Yoshida Y, Hasegawa J, Nishimura J, Hirota M, Kim Y, Nezu R.

Gan To Kagaku Ryoho. 2011 Aug;38(8):1293-6. Japanese.

PMID:
21829066
[PubMed - indexed for MEDLINE]
4.

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P.

BMC Cancer. 2009 Sep 28;9:347. doi: 10.1186/1471-2407-9-347.

PMID:
19785749
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O.

J Clin Oncol. 2009 Jan 10;27(2):199-205. doi: 10.1200/JCO.2008.17.7931. Epub 2008 Dec 8.

PMID:
19064978
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.

Tsutsumi S, Ishibashi K, Uchida N, Ojima H, Hosouchi Y, Yashuda N, Kigure W, Yamauchi S, Asao T, Ishida H, Kuwano H.

Oncology. 2012;83(3):151-7. doi: 10.1159/000337992. Epub 2012 Aug 7.

PMID:
22889925
[PubMed - indexed for MEDLINE]
7.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J.

J Clin Oncol. 2008 Apr 20;26(12):2013-9. doi: 10.1200/JCO.2007.14.9930. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110. J Clin Oncol. 2009 Feb 1;27(4):653.

PMID:
18421054
[PubMed - indexed for MEDLINE]
Free Article
8.

Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.

Suenaga M, Matsusaka S, Ueno M, Yamamoto N, Shinozaki E, Mizunuma N, Yamaguchi T, Hatake K.

Surg Today. 2011 Aug;41(8):1067-74. doi: 10.1007/s00595-010-4432-8. Epub 2011 Jul 20.

PMID:
21773895
[PubMed - indexed for MEDLINE]
9.

Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200.

J Clin Oncol. 2007 Apr 20;25(12):1539-44.

PMID:
17442997
[PubMed - indexed for MEDLINE]
Free Article
10.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators.

Ann Oncol. 2009 Nov;20(11):1842-7. doi: 10.1093/annonc/mdp233. Epub 2009 Apr 30.

PMID:
19406901
[PubMed - indexed for MEDLINE]
Free Article
11.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.

Clin Colorectal Cancer. 2012 Mar;11(1):38-44. doi: 10.1016/j.clcc.2011.05.002. Epub 2011 Jul 29.

PMID:
21803002
[PubMed - indexed for MEDLINE]
12.

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.

Whyte S, Pandor A, Stevenson M, Rees A.

Health Technol Assess. 2010 Oct;14(Suppl. 2):47-53. doi: 10.3310/hta14suppl2/07. Review.

PMID:
21047491
[PubMed - indexed for MEDLINE]
Free Article
13.

5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.

Bir A, Tan W, Wilding GE, Lombardo J, Fakih MG.

Oncology. 2007;72(1-2):4-9. Epub 2007 Oct 30.

PMID:
17971679
[PubMed - indexed for MEDLINE]
14.

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.

Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.

PMID:
18498064
[PubMed - indexed for MEDLINE]
15.

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.

Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y.

Int J Clin Oncol. 2009 Dec;14(6):513-7. doi: 10.1007/s10147-009-0911-6. Epub 2009 Dec 5.

PMID:
19967487
[PubMed - indexed for MEDLINE]
16.

[The usefulness and adverse events of bevacizumab combined with chemotherapy against advanced or recurrent colorectal cancer].

Oga J, Sakata M, Sato S, Matsumura N, Hatakeyama T, Nagayama H, Sakurai O, Ishida Y, Hataya K.

Gan To Kagaku Ryoho. 2010 Jun;37(6):1055-8. Japanese.

PMID:
20567107
[PubMed - indexed for MEDLINE]
17.

Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.

Vaidyanathan G, Groman A, Wilding G, Fakih MG.

Oncology. 2010;79(1-2):67-71. doi: 10.1159/000319549. Epub 2010 Nov 12.

PMID:
21071992
[PubMed - indexed for MEDLINE]
18.

[Continuation of chemotherapy with bevacizumab for advanced and recurrent colorectal cancer].

Soga Y, Ito D, Asano H, Go M, Iwai M, Okada K, Matsuoka T, Adachi S, Usami E, Kimura M, Nakao T, Yoshimura T, Yasuda T, Ogawa T, Iwaki A.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1341-5. Japanese.

PMID:
24105057
[PubMed - indexed for MEDLINE]
19.

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O.

Oncologist. 2009 Jan;14(1):22-8. doi: 10.1634/theoncologist.2008-0213. Epub 2009 Jan 14.

PMID:
19144677
[PubMed - indexed for MEDLINE]
Free Article
20.

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.

Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard JY; GI Group of the French Anti-Cancer Centers.

Int J Cancer. 2011 Feb 1;128(3):682-90. doi: 10.1002/ijc.25369.

PMID:
20473862
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk